Heidelberg Pharma AG

Capital/Financing Update • Feb 6, 2017

News Details

Ad-hoc | 6 February 2017 10:48

WILEX AG Secures Financing Commitment from Its Main Shareholder dievini

WILEX AG / Key word(s): Financing

06-Feb-2017 / 10:48 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by
DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

---

Inside information according to Article 17 MAR

WILEX AG Secures Financing Commitment from Its Main Shareholder dievini

Munich, Germany, 06 February 2017 - WILEX AG (ISIN DE000A11QVV0 / WL6 /
FSE) today announced that it had secured a further financing commitment
from its main shareholder dievini Hopp BioTech holding GmbH & Co. KG,
Walldorf, Germany (dievini). dievini will provide the company up to EUR 10
million. The detailed form of the financing will be decided by the
management and supervisory boards of WILEX AG as well as dievini at a
later date.

With this additional commitment, the company's cash reach is secured until
the end of the second quarter of 2018.

---

Information and Explanation of the Issuer to this News:

About WILEX

WILEX AG is a biopharmaceutical company based in Munich, Germany, that
serves as a parent and holding company. The Company's research and
development work is conducted by its subsidiary Heidelberg Pharma GmbH in
Ladenburg. Heidelberg Pharma is the first company to develop the toxin
Amanitin into cancer therapies using its proprietary Antibody Targeted
Amanitin Conjugate (ATAC) technology and to advance the biological mode of
action of the toxin as a novel therapeutic principle. This proprietary
technology platform is being applied to develop the company's own
therapeutic ATACs as well as in third-party collaborations to create a
variety of ATAC candidates. The proprietary lead candidate is a BCMA ATAC
for multiple myeloma. WILEX's clinical assets MESUPRON(R) and REDECTANE(R)
have been partnered, while RENCAREX(R) is available for out-licensing and
further development. WILEX is listed on the Frankfurt Stock Exchange: ISIN
DE000A11QVV0 / WKN A11QVV / Symbol WL6. More information is available at
http://www.wilex.com/.

Contact IR/PR­support
WILEX AG MC Services AG
Sylvia Wimmer Katja Arnold (CIRO)
Corporate Communications Managing Director & Partner
Tel.: +49 (0)89-41 31 38-29 Tel.: +49 (0)89-210 228-40
Email: investors[at]wilex.com Mobile: +49 (0)160 9360 3022
Grillparzerstr. 18, 81675 Munich Email: katja.arnold[at]mc-services.eu

This communication contains certain forward-looking statements relating to
the Company's business, which can be identified by the use of forward-
looking terminology such as 'estimates', 'believes', 'expects', 'may',
'will' 'should' 'future', 'potential' or similar expressions or by a
general discussion of the Company's strategy, plans or intentions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors, which may cause our actual results of operations,
financial condition, performance, or achievements, or industry results, to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements. Given
these uncertainties, prospective investors and partners are cautioned not
to place undue reliance on such forward-looking statements. We disclaim any
obligation to update any such forward-looking statements to reflect future
events or developments.

---

06-Feb-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

---

Language: English
Company: WILEX AG
Grillparzerstr. 18
81675 München
Germany
Phone: +49 (0)89 41 31 38 - 0
Fax: +49 (0)89 41 31 38 - 99
E-mail: info@wilex.com
Internet: www.wilex.com
ISIN: DE000A11QVV0
WKN: A11QVV
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Munich,
Stuttgart, Tradegate Exchange

 End of Announcement    DGAP News Service